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The serine/threonine kinase PIM1, cooperates with MYC in cell cycle progression and 
tumorigenesis. However, the nature of this cooperation remains elusive. Here we show 
that PIM1 contributes to the transcriptional activation of MYC-target genes by 
phosphorylating the histone H3 nucleosome at Serine 10 (H3S10). Recombinant PIM1 
directly phosphorylates H3S10 on the nucleosome in vitro. Following growth factor 
stimulation, PIM1 accumulates in the nucleus where it forms a complex with the 
MYC/MAX dimer via the MYC BoxII domain (MBII). Immunofluorescence analysis 
coupled with in vivo run-on shows a high degree of PIM1 and MYC co-localization in the 
nucleus at sites of active transcription. Expression profile analysis revealed that PIM1 
contributes to the regulation of 20% of the MYC-regulated genes. Chromatin 
immunoprecipitation (ChIP) analysis in MYC silenced cells demonstrates that MYC 
recruits PIM1 to the E boxes of the MYC-target genes FOSL1 (FRA1) and ID2. PIM1 
knockdown as well as the over-expression of the kinase inactive mutant demonstrate that 
PIM1 is required for H3S10 phosphorylation at FOSL1 and ID2 MYC-binding sites and 
for their transcriptional activation. Moreover, we show that PIM1-dependent H3S10 
phosphorylation contributes to MYC transforming capacity. These results establish a 
new function for PIM1 as a MYC cofactor that phosphorylates the chromatin at MYC-
target loci and suggest that nucleosome phosphorylation, at E boxes, contributes to 
MYC-dependent transcriptional activation and cellular transformation. 
 
Chromatin structure plays a crucial role in eukaryotic gene transcription. Several transcription 
activators have been shown to recruit chromatin-modifying activities, which either mediate 
histone covalent modifications or ATP-dependent nucleosome mobilization. Covalent histone 
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modifications including acetylation, methylation, phosphorylation and ubiquitinylation have 
been associated with gene regulation1,2. Phosphorylation of H3S10 has been connected with 
transcriptional activation in different organisms and with chromosome condensation during 
mitosis3,4. In mammalian cells, growth factor stimulation induces rapid phosphorylation of 
histone H3 at Serine 10 (H3S10) at c-Jun and c-Fos promoters mediated by MSK1, MSK2, and 
RSK2 kinases4-7. In response to inflammatory cytokines, IKK-αphosphorylates H3S10 at NF-
kB-responsive promoters8,9.  
In this study, we analyzed the function of PIM1, a constitutively active serine/threonine kinase. 
Pim1 was first identified as a common insertion site in T cell lymphomas induced by Molony 
murine leukemia virus (Mo-MuLV)10. RNA interference (RNAi) experiments demonstrated 
that human Pim1 (hereinafter referred to as PIM1) is essential for cell cycle progression of 
human umbilical vein endothelial cells (HUVEC) and for differentiation of endothelial 
precursors in vitro11. Myc and Pim1 have been shown to co-operate in cell growth and 
transformation. Pim1 over-expression in transgenic mice demonstrated its cooperation with c-
Myc in cell transformation12-15 and microarray expression profiling showed that Pim1 is over-
expressed in Myc-driven prostate tumours16. However, the nature of c-Myc and Pim1 
cooperation in cell transformation remains elusive.  
Human c-Myc (hereinafter referred as MYC) codes for a basic helix-loop-helix leucine zipper 
(B-HLH) transcription factor that binds to the E box (CACGTG) when dimerized with MAX 
and regulates the transcription of distinct genes involved in cell cycle progression, apoptosis, 
cell growth, and differentiation17-23. The DNA binding domain of MYC is at the C-terminus 
while the N-terminal domain through the MYC boxII (MBII), essential for MYC-dependent 
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cell transformation, has been shown to recruit multiprotein enzymatic complexes to the MYC-
activated genes 24.  
To understand the function of PIM1, we investigated the molecular connection between PIM1 
and MYC. We propose that the recruitment of PIM1 to the chromatin by MYC contributes to 
transcriptional activation of MYC-target genes by phosphorylating H3S10 at the E box 
element and suggest that this cooperation is relevant for MYC-dependent tumour formation.  
 
RESULTS 
 
PIM1 phosphorylates the nucleosome at H3S10.  
PIM1 mRNA is induced with fast kinetics in HUVEC treated with VEGF-A11. Upon VEGF-A 
treatment PIM1 is induced and localizes in HUVEC nuclei within 40 minutes (see 
Supplementary Information Fig. S1). As PIM1 is a serine/threonine kinase with putative 
consensus sites present on histones, its nuclear localization could account for the increase of 
H3 phosphorylation observed in these cells between 60 and 90 minutes after VEGF-A 
treatment (see Supplementary Information Fig. S1).  We found that PIM1 could directly 
phosphorylate nucleosomes in vitro by incubating the recombinant GST-PIM1 protein with 
chromatin fractions obtained from 293 cells in the presence of [γ32P] ATP. This analysis 
revealed that a single protein, with molecular weight corresponding to H3, was phosphorylated 
by wild type GST-PIM1, but not by the kinase inactive mutant GST-PIM1-K67M (Fig. 1a, 
lanes 1-3). Specific inhibition of nucleosome phosphorylation was observed in the presence of 
a peptide derived from the H3 N-terminus but not with a peptide derived from H2B N-
terminus or with an unrelated peptide (Fig. 1a, lanes 4-12). PIM1 could phosphorylate 
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reconstituted nucleosomes containing either recombinant wild type H3 or H3S28A, but not 
nucleosomes assembled with the H3S10A mutant or the double mutant (Fig. 1b) demonstrating 
that PIM1 phosphorylates H3 at S10. Histone H3 co-immunoprecipitated with transiently 
expressed PIM1 or the kinase inactive mutant suggesting that PIM1 associates in vivo with the 
nucleosome (Fig. 1c). Incubation of the immunoprecipitate in the presence of [γ32P] ATP 
showed that the wild type PIM1, but not the kinase inactive mutant PIM1-K67M 
phosphorylated H3. We conclude that PIM1 associates in vitro and in vivo with H3 and 
directly phosphorylates H3S10 on the nucleosome. 
 
PIM1 forms a complex with MYC and MAX.  
VEGF-A treatment induces MYC and PIM1 co-localization in the cell nuclei at 60 minutes, 
decreasing thereafter (Fig. 2a). We tested whether PIM1 coimmunoprecipitaes with MYC. 
Time course analysis in HUVEC treated with VEGF-A showed that upon induction, both 
MYC and PIM1 were induced with fast kinetics. Immunoprecipitations with anti-MAX 
antibodies at various time points showed the formation of the MAX/MYC complex from 60 
minutes after growth factor stimulation thus corresponding to the appearance of MYC in the 
nucleus (Fig. 2b, right panel). Importantly, PIM1 co-immunoprecipitated with MYC and MAX 
suggesting that a complex containing PIM1 is formed. Endogenous PIM1 was also found to 
co-immunoprecipitate with endogenous MYC and MAX  from 293 cells after serum treatment 
for 120 minutes (Fig. 2c), thus demonstrating that a MAX/MYC/PIM1 endogenous complex is 
also formed in these cells.  
As MYC-dependent cell transformation requires MYC boxII (MBII) domain to bind cofactors 
either in a TRRAP-dependent or -independent manner24, we tested whether PIM1 interacts 
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with MYC at MBII via TRRAP. Wild type FLAG-MYC or MYC deleted in the MBII domain 
(FLAG-MYCMBII) were co-expressed with PIM1 in 293 cells and immunoprecipitated 
either with FLAG or PIM1 antibodies. Western blot analysis showed reciprocal 
immunoprecipitation of FLAG-MYC with PIM1, while co-immunoprecipitation was strongly 
reduced between FLAG-MYCMBII and PIM1 suggesting that MBII domain of MYC is 
required for the formation of a complex with PIM1 (Fig. 2d). Endogenous TRRAP associated 
with MYC but not with the FLAG-MYCMBII as previously described 25. In contrast, PIM1 
did not co-immunoprecipitate the endogenous TRRAP (lanes 5 and 10) suggesting that MYC 
forms independent complexes with PIM1 or TRRAP via the MBII domain.  
 
PIM1 co-localizes with MYC on the chromatin at actively transcribing loci.  
To measure PIM1 and MYC association at MYC-target genes, we performed a nuclear 
distribution analysis of PIM1 with respect to MYC, nascent transcripts, and chromatin markers. 
Quantitative analysis of double staining with anti-PIM1 and antibodies against different 
nuclear markers by sequential laser scanning (Fig. 3) showed an elevated degree of PIM1 co-
localization with MYC with a Pearson’s correlation coefficient (Rr) of 0.82±0.06. PIM1 also 
showed an elevated overlap with H3S10ph (Rr 0.85±0.07) and H3S10phK14ac while little co-
localization could be detected between PIM1 and H3K9me2 (Rr 0.37±0.03), a marker of silent 
heterochromatin. Furthermore, we analyzed the nuclear distribution of PIM1 with respect to 
active transcription sites by in situ transcriptional run-on experiments. Double labelling 
revealed a high degree of overlap between PIM1 and sites of active transcription (Rr  
0.77±0.05) with a pattern resembling that of transcription factories26. A similar pattern of 
nuclear localization with respect to nascent transcripts was observed for MYC (Rr  0.81±0.09). 
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Taken together these results suggest that following growth factor treatment PIM1 kinase is 
mostly localized with the transcription factor MYC at actively transcribing sites and with 
phosphorylated histones. 
 
H3S10 phosphorylation at the FOSL1 enhancer correlates with PIM1 association. 
Next we analysed PIM1 association and H3S10 phosphorylation at FOSL1 (also known as 
FRA1), a well characterized MYC-target gene27,28. FOSL1 contains an upstream functional 
SRE, which is not sufficient to confer promoter activation, but requires the activity of a 
downstream enhancer that is activated by MYC and AP-127-29. Upon VEGF-A treatment of 
HUVEC FOSL1 expression is induced with a peak at 60 minutes (Fig. 4a). To demonstrate a 
direct binding of MYC and PIM1 to the FOSL1 regulatory sequences ChIP followed by real-
time quantitative PCR analysis was performed at various timepoints after VEGF-A treatment. 
As shown in Figure 4b, we generated primers to analyze four FOSL1 regions: a FOSL1 
upstream region containing a functional SRE and a non canonical E box element30,31 (probe A), 
the downstream enhancer containing a canonical E box (probe B), a downstream region within 
the first intron (probe C), and a FOSL1 region within the second intron (probe D). Quantitative 
ChIP analysis with probe B revealed the transient recruitment to the FOSL1 enhancer of MYC 
and PIM1 from 60 minutes concomitant with a marked increase of H3S10ph signal (Fig. 4c). 
ChIP with probe B also showed a significant increase of H3S10phK9ac and H3S10phK14ac 
while H3K9acK14ac showed elevated levels before induction suggesting that, at the FOSL1 
enhancer, H3 acetylation precedes MYC binding and H3S10 phosphorylation takes place at the 
acetylated H3.  
Analysis of the upstream element (probe A) revealed MYC association with this DNA 
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fragment. PIM1 did not associate with this element suggesting that the FOSL1 promoter is 
bound by an alternative MYC complex. This FOSL1 upstream element showed an increase of 
H3S10 phosphorylation at 15 minutes after VEGF-A treatment, which was therefore not 
dependent on PIM1. As the FOSL1 SRE element is constitutively occupied by the ternary 
complex factor (TCF), which is activated by the RAS/ERK pathway30, we further analyzed 
FOSL1 transcription and H3S10 phosphorylation in the presence of H89, a specific 
MSK1/MSK2 inhibitor5. Cell treatment with H89 affected FOSL1 transcription although a 
VEGF-A-dependent induction was still observed (Fig. 4d). The analysis of H3S10ph signal 
showed specific inhibition of H3S10 phosphorylation at the FOSL1 upstream element but not 
at the enhancer (Fig. 4e) demonstrating that phosphorylation at the upstream element and at the 
downstream enhancer are independent from each other and mediated by different kinases. The 
acetylation pattern at the FOSL1 upstream element showed a significant increase of H3 
phosphorylation and acetylation with a peak between 15 and 30 minutes suggesting that, at this 
site, H3S10 phosphorylation precedes or is concomitant with H3 acetylation at K9 and K14 as 
previously described for IE promoters3,4.   
The downstream FOSL1 fragments (analyzed with probes C and D) did not reveal MYC or 
PIM1 binding, nor the increase of phosphorylated H3S10, while presented elevated levels of 
acetylated H3. These results demonstrate specific recruitment of PIM1 to the FOSL1 enhancer 
concomitant with an increase of H3S10 phosphorylation at this site and with transcriptional 
activation of the gene.    
 
H3S10 phosphorylation at FOSL1 enhancer is mediated by PIM1. 
PIM1 depletion using small hairpin RNA (shRNA) was peformed to test whether PIM1 
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association with the FOSL1 enhancer was required for H3S10 phosporylation. In 293 cells 
treated with serum MYC, PIM1, and FOSL1 showed a slower kinetics of induction with 
respect to HUVEC treated with VEGF-A possibly due to the different cell types (cell line 
versus primary cells). PIM1 silencing strongly inhibited FOSL1 mRNA expression (Fig. 7b 
and see Supplementary Information Fig. S3). Quantitative ChIP analysis (Fig. 5b and see 
Supplementary Information Fig. S2) demonstrated a peak of H3S10 phosphorylation at the 
FOSL1 enhancer (probe B as described in Fig. 4b) at 120 minutes that was significantly 
reduced by PIM1 silencing, while ChIP analysis at the FOSL1 upstream element (probe A) 
showed a faster kinetics of H3S10 phosphorylation that was not affected by PIM1 knockdown. 
No H3S10 phosphorylation was observed at the downstream fragments (probes C and D). We 
concluded that H3S10 phosphorylation at the FOSL1 enhancer is PIM1-dependent.  
PIM1 and MYC are found to associate at the FOSL1 enhancer with a peak between 90 and 120 
minutes. PIM1 silencing significantly reduced PIM1 association at the enhancer without 
affecting MYC association. The overall pattern of H3 phospho-acetylation at K9 and K14 in 
293 cells showed elevated levels of H3 acetylation already present before H3 phosphorylation 
at the FOSL1 enhancer (probe B) and along the FOSL1 gene (probe C and D) which was not 
affected by PIM1 silencing.  
Moreover, expressing the kinase inactive mutant PIM1-K67M, significantly reduced H3S10ph 
levels at the FOSL1 enhancer (see Supplementary Information Fig. S4) demonstrating that the 
kinase activity of PIM1 is required for H3S10 phosphorylation at this site.  
 
PIM1 is recruited by MYC at the FOSL1 and ID2 E box elements. 
MYC silencing was performed to analyze whether its expression is required for PIM1 
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recruitment to the FOSL1 enhancer (Fig. 6a and see Supplementary Information Fig. S5). We 
also analyzed MYC-dependent recruitment of PIM1 at the ID2 E box. ID2 is a well 
characterized MYC-regulated gene that, differently from FOSL1, contains its functional MYC-
binding sites upstream the promoter28,32. As expected, ChIP analysis on control cells showed 
MYC association at the FOSL1 enhancer and the ID2 E box at 120 minutes after serum 
treatment, while MYC silencing significantly reduced MYC association at these sites (Fig. 6b 
and see Supplementary Information Fig. S5). ChIP analysis revealed PIM1 association with 
both genes in control cells while MYC knockdown significantly reduced PIM1 association at 
these E boxes (Fig. 6c and see Supplementary Information Fig. S5). Moreover, H3S10 
phosphorylation showed significant reduction in MYC silenced cells at these sites (Fig. 6d and 
see Supplementary Information Fig. S5). In contrast, H3K9acK14ac was unaffected by MYC 
silencing (Fig. 6e and see Supplementary Information Fig. S5) confirming that H3 acetylation 
is not dependent on MYC binding. Importantly, the reintroduction of wild type FLAG-MYC, 
but not the FLAG-MYCMBII in MYC-silenced cells restored PIM1 recruitment and H3S10 
phosphorylation at both sites (Fig. 6 f, g, h and see Supplemenrary Information Fig. S5). These 
results establish that MYC, via its MBII domain, recruits PIM1 to the E box elements of these 
MYC-regulated genes and its recruitment is required for phosphorylating H3S10 at these sites.  
 
PIM1 is required for transcriptional activation of FOSL1 and ID2 genes. 
After serum treatment of 293 cells, both FOSL1 and ID2 mRNA were induced with similar 
kinetics (Fig. 7b, e) corresponding to the peak of PIM1 and MYC association and H3S10 
phosphorylation in these cells. The same results were obtained by measuring FOSL1 and ID2 
unprocessed heterogeneous nuclear RNA (hnRNA) indicating that increased mRNA level 
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depend on transcriptional activation. PIM1 silencing, as well as the expression of PIM1-K67M, 
inhibited induction of both FOSL1 and ID2 transcripts (Fig 7b, e and see Supplementary 
Information Fig. S6) demonstrating that PIM1 kinase activity is required for full transcriptional 
activation of both genes.   
Quantitative ChIP analysis of RNA Polymerase II (Pol II) and as well as Pol II phosphorylated 
in Ser2 (Ser2P) at the C-terminal domain (CTD) of control cells revealed a significant increase 
in signal at FOSL1 and ID2 promoters and along the genes in response to serum treatment (Fig. 
7c, f and see Supplementary Information Fig. S6) mirroring of the increase in transcript levels. 
PIM1 silencing led to a specific reduction of Pol II signal  at the promoters and within the 
coding regions. This reduction, however, could not account for the inhibition of the 
transcriptional activity mediated by the PIM1 silencing. By contrast, the reduction of the 
elongating Pol II (Pol II-Ser2P) along the gene more closely correlated with transcript levels of 
both FOSL1 and ID2 suggesting that PIM1 silencing mostly affects the presence of Pol II 
engaged in transcript elongation.   
 
PIM1 contributes to the regulation of a subgroup of MYC-regulated genes.  
To understand the extent of PIM1 and MYC co-operation in gene transcription we performed 
expression profile analysis of 293 cells silenced either for MYC or PIM1 at 120 minutes after 
serum treatment. MYC silencing affected the expression of 1026 genes of which 818 were up-
regulated and 208 were down-regulated (see Supplementary Information Table SI) in line with 
previous analysis of MYC-regulated genes33. Comparison of genes regulated by MYC with 
those regulated by PIM1 showed that PIM1 contributes to the regulation of 207 genes out of 
the 1026 MYC-regulated genes. Thus, 20% of MYC-regulated genes, are also regulated by 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
00
.1
 : 
Po
st
ed
 1
9 
Ju
n 
20
07
  12
PIM1. Functional characterization of these genes, based on Gene Onthology categorization 
through the Panther database (http://www.pantherdb.org), revealed that nucleic acid 
metabolism, transcriptional regulation, RNA processing, and oncogenesis are statistically 
overrepresented (P<0.05) (see Supplementary Information Table SII, SIII). Based on this 
analysis we conclude that PIM1 act as a cofactor for transcriptional regulation in a significant 
subset of MYC-dependent genes.  
 
PIM1 recruitment to the chromatin by MYC contributes to cell transformation. 
Next we investigated the biological relevance of MYC - PIM1 co-operation. First we verified 
whether PIM1 contributes to MYC-dependent regulation of cell cycle progression by silencing 
PIM1 in P493-6 cells, a cell line that depends on MYC expression for its proliferation27,34,35. 
Incorporation of [3H] thymidine was significantly decreased in PIM1 silenced cells and 
analysis of the cell cycle by FACS showed that PIM1 depletion determines a delay in S phase 
progression of these cells (see Supplementary Information Fig. S7).   
To test whether PIM1 cooperation with MYC in cell transformation and tumour growth is due 
to PIM1’s role in transcriptional activation of MYC-target genes, we performed transformation 
experiments in Rat-1 fibroblasts. Over-expression of MYC transforms these cells 
morphologically and induces them to grow in soft agar36. PIM1 silencing strongly inhibited the 
formation of soft agar foci, induced by MYC over-expression, and MYC silencing affected the 
number of foci induced by PIM1 over-expression to a similar extent,  (Fig. 8a) thus, 
demonstrating that PIM1 is indeed required for MYC-dependent cell transformation. Moreover, 
the over-expression of MYC and PIM1 generates a significantly higher number of soft agar 
colonies than cells over-expressing either MYC or PIM1 (Fig. 8a, b).  
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To understand whether PIM1 acts as a MYC cofactor in cell transformation we generated 
chimeric constructs in which PIM1 was directly fused to the N terminal domain of MYC 
(PIM1-MYC). We found that the PIM1-MYC fusion molecule induced a comparable number 
of soft agar colonies relative to the co-expression of MYC and PIM1 in the same cells (Fig. 8b) 
suggesting that PIM1 recruitment to the chromatin by MYC is required for cooperation 
between MYC and PIM1 in cell transformation. Since formation of the MYC complex with 
PIM1 and its recruitment to MYC binding sites requires the MYC MBII domain (Fig. 2, 6), 
which is essential for MYC oncogenic activity, PIM1 was also fused to the transformation-
defective MYC deleted in the MBII domain. Interestingly, we found that the fusion PIM1-
MYCMBII, but not co-transfection of MYCMBII with PIM1, was able to rescue, at least in 
part, the defective MYC-transformation (Fig. 8b). Importantly, this fusion rescues both 
transcriptional activity and ability to phosphorylate H3S10 at its recruiting sites (Fig. 8d, f). In 
contrast, a chimeric molecule in which PIM1 was fused to a MYCC, a mutant unable to bind 
to the DNA, was defective for transforming activity and for phosphorylation of H3S10 at the 
target genes analysed (see Supplementary Information Figure S8). Interestingly, the 
transformed foci induced by the PIM1-MYC fusion grew vigorously in soft agar forming 
bigger colonies as compared with PIM1KD-MYC (see Supplementary Information Fig. S8). 
Finally, we tested whether H3 phosphorylation at S10 is required for MYC-dependent 
transformation by analysing MYC transforming potential in the presence of either yellow 
fluorescent protein (YFP) fused to H3 (YFP-H3) or to H3 mutated in S10 (YFP-H3S10A). 
Both fusion proteins co-localised in the nucleus during interphase and mitosis together with the 
endogenous H3S10ph (see Supplementary Information Fig. S9) and they did not interfere with 
cell cycle progression (see Supplementary Information Fig. S9) as previously reported for 
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other histone fusion proteins37. Then we performed transformation assays by either expressing 
MYC, PIM1 or PIM1-MYC fusion proteins in these cells (see Supplementary Information Fig. 
S10). We observed that, while YFP-H3 did not affect the number of foci, YFP-H3S10A 
mutant significantly reduced the number of soft agar colonies, FOSL1 and ID2 transcription as 
well as H3 phosphorylation at their MYC binding sites (see Supplementary Information Fig. 
S10).  
Taken together these results show that H3 phosphorylation at MYC-target genes by PIM1 is 
required for the cooperative effects of PIM1 and MYC in cell transformation.   
 
DISCUSSION  
 
This study defines a new role for the serine/threonine kinase PIM1 as a MYC-dependent 
modifier of the chromatin. Based on biochemical and functional evidence, we show that 
following growth factor stimulation a MYC/MAX/PIM1 complex, formed in the nucleus, 
recruits PIM1 to the chromatin where it phosphorylates H3 at S10. This PIM1-dependent 
nucleosome phosphorylation is required for the transcriptional activation of a subset of MYC-
target genes and MYC-dependent cell transformation.  
Immunoprecipitation experiments showed that following growth factor stimulation MYC, in 
conjunction with MAX, forms a complex with PIM1 in the nucleus. Silencing experiments 
demonstrated that MYC is required for PIM1 recruitment to the chromatin while PIM1 is 
necessary to phosphorylate the H3 at S10 on the nuclesosme at E boxes to activate the 
transcription.  According to the current view phosphorylation at the N-terminal domain of H3 
could either be required to loosen the interaction between DNA and nucleosome and/or to 
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generate a platform to recruit additional regulatory factors as described in the “histone code” 
hypothesis1. PIM1-dependent phosphorylation at the FOSL1 and ID2 genes is specific for its 
recruitment sites and does not spread over the genes, suggesting that this phosphorylation is 
necessary to trigger the enhancer to its active state.  
It was previously shown that upon growth factors treatment H3 is phosphorylated at S10 with 
fast kinetics by MSK1/MSK24-7. Interestingly, FOSL1 shows two regions with different 
phosphorylation kinetics of H3S10: a phosphorylation site at the upstream SRE element, 
occurring within 15-30 minutes due to MSK1/MSK2, and a phosphorylation at the enhancer 
that was coincident with the peak of transcriptional activation of the gene mediated by PIM1. 
These two regions behaved differently with respect to acetylation of H3 at K9 and K14. While 
at the FOSL1 promoter H3 phosphorylation and acetylation are tightly coupled as previously 
shown for other IE promoters3,38-40, at the FOSL1 enhancer, phosphorylation of H3S10 takes 
place in a region highly acetylated at H3 prior to MYC and PIM1 binding in agreement with 
the finding that for MYC recognition its target sites must be highly acetylated in H3 as well as 
methylated in H3K4/K7941. On the FOSL1 enhancer phosphorylation and acetylation of H3 
might have distinct functional roles as PIM1-dependent H3S10 phosphorylation is transient 
and limited to the E box element while acetylation at K9 and K14 is more stable and 
distributed along the gene suggesting that phosphorylation at these elements represents a 
critical step for the transcriptional activation. The fast turnover of H3 phosphorylation 
observed in our experiments and its temporal coincidence with transcriptional activation might 
be a general phenomenon as H3 phosphorylation was previously detected with the 
transcriptional activation of heat shock genes in Drosophila and with the RAR2 gene 
induction by retinoic agonists in murine P19 embryonal cells while acetylation was 
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constitutive at these loci42,43.  
It has been estimated that about 11% of cellular genes present a functional E box to which 
MYC can associate on the genome28. MYC silencing demonstrated that MYC recruits PIM1 at 
specific MYC binding sites and confocal microscopy showed an elevated degree of nuclear co-
localization of PIM1 with nascent transcripts and with MYC following growth factor treatment, 
suggesting that, at this stage of the cell cycle, PIM1 is recruited by MYC to a large number of 
sites. Gene expression profile analysis of MYC and PIM1 regulated genes in cells treated with 
serum at 120 minutes, revealed that 207 transcripts, corresponding to 20% of MYC regulated 
genes, also require PIM1 for their regulation. The co-regulation includes genes involved in cell 
metabolism, protein synthesis, cycle progression, and oncogenesis. Interestingly, a large 
number of genes are transcriptional factors, which suggests that PIM1 participates in MYC-
dependent regulatory networks. In agreement with these data cell cycle analysis, in PIM1 
knockdown cells, revealed reduced entry in the S phase. Transformation analysis showed a  
more dramatic PIM1 effect as PIM1 silencing strongly inhibited the formation of MYC-
dependent transformed soft agar colonies. Although our experiments do not exclude that 
specific PIM1-regulated genes co-operate with MYC in cell transformation, our data strongly 
suggest that PIM1-dependent phosphorylation of H3 at MYC-target genes is necessary to 
regulate key genes required for MYC-dependent oncogenic transformation. In fact, PIM1 
fusion to the transformation defective MYCMBII could significantly rescue its transforming 
potential as well as H3 phosphorylation at MYC binding sites while PIM1 co-expression with 
MYCMBII did not rescue.  
In conclusion, this study provides a molecular mechanism for MYC and PIM1 cooperation in 
gene regulation and oncogenic transformation. As mutations that alter MYC expression are 
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among the most common found in human and animal cancers44, it is conceivable that 
inhibiting MYC association with PIM1 and/or inhibiting PIM1 kinase activity by specific 
drugs might represent a method for the treatment of cancers in humans.  
 
METHODS  
 
DNA constructs. Human PIM1 and MYC cDNA were cloned into pcDNA5/FRT (Invitrogen) 
vector under the control of the CMV/TetO2 tetracycline inducible promoter. The PIM1-K67M 
construct was generated by introducing a site-specific mutation in the DNA sequence 
corresponding to the lysine 67 to mutate it into a methionine (K67M). The MYCMBII 
construct was obtained by deleting the DNA sequence corresponding to the amino acids 119-
152. The MYCC construct was obtained by deleting the DNA sequence corresponding to the 
amino acids 353-439. The PIM1-MYC fusion constructs were obtained by fusing the cDNA 
corresponding to PIM1 or PIM1-K67M via a 10 glycine encoding linker sequence to the 
cDNA corresponding either to MYC, MYCMBII or MYCC.  
shRNA constructs were obtained by cloning a double-stranded DNA cassettes into the 
pENTR/H1/TO vector, which allows the expression of shRNA under the control of the 
tetracycline inducible H1 promoter/TetO2.  
To generate shRNA cassettes the following oligonucleotides were designed following the 
manufacturer’s protocol. The 21-nucleotides positive strands are:  
PIM1 shRNA#1 (shPIM1#1):  5’-GTCTCTTCAGAGTGTCAGCAC-3’ 
PIM1 shRNA scrambled control#1 (shsP#1): 5’-GACTCATCAGTATGTTAGCAT-3’  
PIM1 shRNA#2 (shPIM1#2): 5’-GAGGAAGAGAGTATCTATGGG 
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PIM1 shRNA scramble control#2 (shsP#2): 5’-GAAGCCGAGAGTATCTATGTT -3’ 
PIM1 shRNA#3 (shPIM1#3):  5’-CGAAGAAATCCAGGACCATCC -3’ 
PIM1 shRNA scrambled control#3 (shsP#3): 5’-AAGTCATCCGAAGACCACAAC-3’ 
PIM1 shRNA#4 (shPIM1#4):  5’-ACGTGGAGAAGGACCGGATTT-3’ 
PIM1 shRNA scrambled control #4 (shsP#4): 5’-GATTCGAGGACATGGACTGAG-3’ 
c-MYC shRNA#1 (shMYC#1):  5’-GCAATCACCTATGAACTTGTT-3’  
c-MYC shRNA scramble control#1(shsM#1): 5’-GCATTCACCTAAGAAGTTCTT-3’   
c-MYC shRNA#2 (shMYC#2): 5’- GACGACGAGACCTTCATCAAA -3’ 
c-MYC shRNA2 scramble control #2 (shMYC#2): 5’-AGATCCAACCAGTCAGGACAT– 3’ 
c-MYC shRNA#3 (shMYC#3):  5’-CCTGAGACAGATCAGCAACAA-3’  
c-MYC shRNA scramble control#3 (shsM#3): 5’-CAACATGGTAACGAACAGCAA -3’ 
c-MYC shRNA#4 (shMYC#4):  5’-CAGTTGAAACACAAACTTGAA-3’  
c-MYC shRNA scramble control#4(shsM#4): 5’-AACTAAGGTAACTATGCACAA-3’ 
c-MYC shRNA#5 (shMYC#5):  5’-CCATAATGTAAACTGCCTCAA-3’  
c-MYC shRNA scramble control #5(shsM#5): 5’-GCAATGACCACCTATTCAATA-3’ 
The recombinant GST-PIM1 construct was obtained by cloning the PIM1 WT and PIM1-
K67M cDNA into the bacterial expression vector pGEX-4T and the fused protein was 
expressed and purified using the standard protocol. 
The vector coding for Xenopus leavis histones were expressed and purified as previously 
described 45. Mutant recombinant histones H3 (H3S10A, H3S28A, H3S10A/S28A) were 
obtained by site directed mutagenesis as previously described 46.  YFP-H3 was kindly provided 
by Marco Bianchi and mutagenized as previously described 46.  
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Cell culture condition. We generated tetracycline inducible 293 cell line stably expressing 
PIM1 WT or PIM1-K67M by using the Invitrogen’s Flp-T-Rex System. 
pCDNA5/FRT/TO expression vector containing the gene of interest was inserted into the cells 
via Flp recombinase-mediated DNA recombination at the FRT site. The transfected cells were 
selected on the basis of hygromycin B (Sigma) resistance and pool clones were isolated. 
Selected clones were cultivated in Dulbecco modified essential medium (D-MEM) containing 
10% fetal bovine serum (FBS; Sigma) and 150µg/ml hygromycin for 2/3 weeks. 
To perform time course experiments 293 cells were synchronized and then treated with 50% 
serum shock as described 47. Primary HUVEC cells were grown in M199 medium 
supplemented with 15% fetal bovine serum, brain protein extracts and heparin (50g/ml). The 
cells were then starved for 24 hours in M199 medium containing 1% FBS and 0.5% BSA and 
induced with 50 ng/ml of VEGF-A. 
The cell line P493-6 (kindly provided by Bruno Amati) were grown in RPMI 1640 containing 
10% fetal calf serum (FCS) 100 U/ml penicillin, 100µg/ml streptomycin 2mM L-glutammine. 
MYC repression was obtained with 0.1 µg/ml tetracycline. MYC induction was obtained by 
washing the cells three times with tetracycline fee phophate buffered saline containing 10% 
FCS as previously described27.    
 
Immunostaining and co-localization analysis. Co-localization experiments were performed 
on fixed cells as previously described11 using a Leica TCS SP2 confocal microscopy. To label 
nascent RNA, anti-BrUTP (Sigma cat. B2531) has been utilized in permeabilized cells by 
immunodetection with small modifications from previously described protocol48. The degree 
of double staining was measured by quantitative analysis of the overlapping pixel using the 
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Image J 1.32j (NIH, USA) software. All pixels having the same position in both images are 
considered coincident and the brightness level of each pixel is plotted as x and y axis of the 
scatter diagram. Two completely overlapping images will result in a straight diagonal line in 
scatter diagram. 
 
Protein immunoprecipitation, interaction, kinase assays, chromatin immunoprecipitation. 
Proteins were extracted using F-buffer (10mM TRIS pH7.0, 50mMNaCl, 30mM Na2HPO4, 
50mM NaF, 5µM ZnCl2, 1% Triton-X 100) and treated with 1U/ml Micrococcal nuclease 
(Sigma) at 40C for 1hr to obtain the chromatin proteins (Chromatin fraction).  
To identify interacting protein, 0.5 mg of total proteins was incubated with 3g of specific 
antibody overnight at 4° C. Immunocomplexes were incubated with Protein A- or G-
conjugated magnetic beads (DYNAL) for 30 minutes at 4°C. Samples were washed four times 
with F buffer and 2 times with 0,15M NaCl F-buffer for 20 minutes at 4°C. Proteins were 
eluded by boiling the samples and analysed by western blotting. 
GST-interaction assay was performed by incubating 1mg of protein extracts (derived from 
chromatin fractions) with recombinant proteins GST, GST-PIM1WT and GST-PIM1-K67M 
bound to Glutathione-sepharose resin (Amersham). To allow specific interactions, proteins 
were incubated in Interaction buffer (TRIS 20mM; KCl 200mM; DTT 10mM; EGTA 0,1mM; 
Glycerol 20%; Inhibitor protease cocktail) for 2 hours at 4°C in presence of 21-aa peptides. 
Unbound proteins were eliminated by 3 washes in the same buffer followed by protein 
equilibration in the Kinase buffer (TRIS 30mM; DTT 10mM; EGTA 0,1mM MnCl 2mM; 
Glycerol 10%). Kinase assay was performed by incubating samples in the same buffer in 
presence of 4 pmol of [γ-32P] ATP for 2 minutes at 30°C. Reaction was stopped by adding 
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10mM EDTA and samples were washed 6 times with Kinase buffer containing 10mM EDTA 
and 200mM KCl. Phosphorylated proteins were separeted by SDS-PAGE and visualized by 
autoradiography. 
Nucleosome core particles (NCPs) reconstitution was carry out as described 49.  
Chromatin Immunoprecipitation (ChIP) assays were performed as described by Upstate 
protocols (www.upstate.com). DNA was analyzed by quantitative real-time PCR by using 
Light Cycler DNA Amplification Kit SYBR Green I (Roche, Mannheim, Germany). All 
experiment values were normalized to those obtained with a non-immune serum and divided 
by input, using the procedure previously described 50. Experiments of MSK1/MSK2 inhibition 
were performed by incubating cells with H89 (Calbiochem) as previously described 5. 
Oligonucleotide sequences will be provided upon request.  
Quantitative RT-PCR analysis was performed as previously described11.  
 
Cell transformation and colony formation in soft agarose 
The analysis of cell transformation and anchorage independent growth were performed as 
previously described 36. Cells transfected with the constructs indicated were   
suspended at approximately 1x104 cells in 2 ml of 0.35% low-melting agarose onto  35-mm 
culture dish containing 0.7% agarose base. Triplicates were prepared for each tested construct 
and inspected by eye after crystal violet staining for colony formation after incubation at 370C 
for 10-14 days. Efficiency of transfection was measured by reporter GFP gene and the levels of 
proteins were compared by Western blotting.  
  
Antibodies 
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The antibodies used for in this work are purchased by Santa Cruz Biotechnology (anti-PIM1 
SC-7856 for ChIP and immunofluorescence experiments; anti-PIM1 SC-13513 for Western 
blot analysis; anti-Myc SC-764 for ChIP and immunofluorescence experiments and anti-Myc 
SC-40 for Western blot analysis; anti-MAX SC-197 and SC-765; anti-SP1 SC-59; anti-Pol II 
SC-899), by Covance anti Pol II Ser2 H5, by Upstate (anti-Histone H3 06-755; anti-acetyl 
Histone H3 06-599; anti-phospho (Ser10)-acetyl (Lys14)-Histone H3 07-081; anti-phospho 
(Ser10)- Histone H3 05-817), and by Abcam anti phospho (Ser10)-acetyl (Lys9)-Histone H3 
Ab 12181-50. 
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FIGURE LEGENDS 
 
Figure 1. PIM1 phosphorylates H3S10 on the nucleosome.  
(a) PIM1 phosphorylates histone H3 on nucleosomes from chromatin fraction. GST-
recombinant proteins, as indicated, were incubated with purified nucleosomes from 
293 cells and the kinase reactions were carried out in the presence of [γ32P] ATP. 
GST-PIM1 interactions with nucleosomes were performed in the absence (-) or 
presence of 20 fold molar excess of unrelated (unr), H3 or H2B peptides as indicated. 
GST recombinant proteins and nucleosomes were visualized by Coomassie staining. 
Histone phosphorylation was revealed by autoradiography. H3 but not H2B N-terminal 
domain competes for PIM1 association to the nucleosome inhibiting the kinase 
reaction.  
(b) PIM1 phosphorylates histone H3 at serine 10. Recombinant GST-PIM1 or the 
PIM1 kinase inactive mutant were incubated with nucleosomes reconstituted in vitro 
from recombinant histones. Nucleosomes were assembled containing respectively the 
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histone H3 wild type (lanes 1, 2), the mutant H3S10A (lanes 3,4), the mutant H3S28A 
(lanes 5,6) or the double mutant H3S10A/S28A (lanes 7,8). Histone H3 
autoradiography resulting from [γ-32P] ATP incorporation (first panel) is shown. The 
input kinases and nuclesomes were visualized by Coomassies staining (lower panels).   
(c) PIM1 interacts with histone H3 in vivo. PIM1 was immunoprecipitated from 293 
stable clones expressing the inducible PIM1 (WT) or the kinase inactive mutant PIM1-
K67M (K67M) as indicated. PIM1 and H3 were revealed by immunoblotting (IB) with 
specific antibodies. A kinase reaction (KA) was carried out incubating the PIM1/H3 co-
immunoprecipitate in the presence of [γ32P] ATP. Histone phosphorylation was 
visualized by autoradiography. 2% of the total immunoprecipitated protein samples 
were loaded as inputs (lower panel). 
  
Figure 2.  PIM1 forms a complex with MYC.  
(a) PIM1 co-localizes with MYC in HUVEC upon VEGF-A treatment. Indirect 
immunofluorescence analysis of HUVEC treated with VEGF was performed by using 
antibodies against PIM1 (red) and MYC (green) and double immunostaining are 
shown (Scale bar = 70µm).  
(b) VEGF-A treatment induced interaction of endogenous PIM1 with the MYC/MAX 
dimer. Cell proteins extracted from VEGF-A treated HUVEC were either 
immunostained (INPUT) or subjected to immunoprecipitation (IP) with anti-IgG 
antibodies (-), or anti-MAX antibodies as indicated (+). Immunostaining (IB) analysis 
was performed by using anti-MAX, -MYC and -PIM1 antibodies as indicated. 10% of 
the total immunoprecipitated protein samples were loaded as inputs.  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
00
.1
 : 
Po
st
ed
 1
9 
Ju
n 
20
07
  30
(c) Endogenous PIM1 forms a complex with MYC/MAX in serum-stimulated 293. 
Western Blot analysis of input extracts, IgG, MAX, MYC or PIM1 immunoprecipitates 
from serum induced or not induced as indicated. Interacting proteins were revealed by 
using anti-MAX, -MYC, or  -PIM1 antibodies respectively. 
(d) MYC forms a complex with PIM1 through its MBII domain. 293 were transiently co-
transfected with FLAG-MYC constructs as indicated and PIM1. Cell lysates were 
immunoprecipitated with anti-IgG, anti-FLAG, or anti-PIM1 antibodies followed by 
Western blot analysis to detect MAX, MYC, PIM1 and TRRAP proteins as indicated. 
Asterisk indicated an unspecific band.  
 
Figure 3. PIM1 co-localizes with H3S10ph, active chromatin, and MYC.  
(a) Immunofluorescence analysis of PIM1 nuclear sub-localization in HUVEC treated 
with VEGF for 60 minutes. Fixed cells were double-stained for PIM1 (red) and one of 
the indicated markers (green) (Scale bar = 8µm). The corresponding pictures were 
merged and all pixels having the same position in both images are considered 
coincident and were represented as white spots (co-localization points). The 
brightness level of each pixel is plotted as x (PIM1) and y (marker) axis of the scatter 
diagram of the correlation plot. The pixels co-localization results of 7 individual images 
represented in the correlation plot were quantified as Pearson’s correlation coefficient 
(Rr) as mean ± SD with P values determined using Student's t-test.  
(b) Immunofluorescence analysis of  MYC localization at transcriptional active sites. 
Cells were labeled with BrUTP and detected with anti-bromodeoxyuridine antibody 
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(green). Double labeling was revealed at transcriptional active sites by staining cells 
with an anti-MYC antibody (red). The pixels co-localization were performed as in (a).  
 
Figure 4. PIM1 associates to chromatin at the FOSL1 enhancer.  
(a) FOSL1 is transiently induced by VEGF-A treatment. Serum-starved HUVEC were 
treated with VEGF-A and total RNAs were collected at different time points. FOSL1 
transcript levels were quantified by quantitative RT-PCR and relative values 
normalized on GAPDH expression level. A representative experiment is shown. The 
data represent triplicate real-time quantitative RT-PCR measurements.  
(b) Schematic representation of the FOSL1 gene region including the first two exons 
(not in scale). Exons are represented as black squares within the gene and the E box 
is figured as a black spot. The probes used in ChIP analysis are indicated. PCR 
probes intervals are numbered relatively to the fist nucleotide of exon 1 (+1). 
(c) VEGF-A induces PIM1 association with chromatin at the FOSL1 enhancer. Protein 
interactions on FOSL1 chromatin were measured by quantitative ChIP assay on 
VEGF-A-treated HUVEC. Chromatin extracts were immunoprecipitated using 
antibodies as indicated. A representative experiment is shown. The data represent 
triplicate real-time quantitative PCR measurements of the immunoprecipitated DNA of 
the corresponding gene regions identified as probes A, B, C or D at different time 
points and expressed as 1/1000 (‰) of the DNA inputs. 
(d) FOSL1 expression in the presence of MSK1/MSK2 inhibitor H89. Serum-starved 
HUVEC were treated with VEGF-A in the presence or absence of 10 µM H89 and total 
RNAs were collected at different time points. FOSL1 transcript levels were quantified 
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by real-time quantitative RT-PCR and relative values normalized on GAPDH 
expression level. A representative experiment is shown. The data represent triplicate 
real-time quantitative RT-PCR measurements.  
(e) Phosphorylation of H3S10 at the FOSL1 upstream element is dependent from 
MSK1/MSK2 kinase activities. H3S10 phosphorylation was measured by quantitative 
ChIP assay on VEGF-A-treated HUVEC. Chromatin extracts were immunoprecipitated 
using antibodies as indicated. A representative experiment is shown. The data 
represent triplicate real-time quantitative PCR measurements of the 
immunoprecipitated DNA of the corresponding gene regions identified as probes A, B, 
C or D at different time points and expressed as 1/1000 (‰) of the DNA inputs.  
 
Figure 5.  PIM1 mediates H3S10 phosphorylation and contributes to FOSL1 
transcription. 
(a) Inducible shRNA expression targeting PIM1. Western blot analysis of 293 stable 
clones expressing a control scrambled shRNA (shsP#1) or PIM1 shRNA (shPIM1#1) 
inducible by tetracycline. Immunostaining with antibodies as indicated. Protein 
extracts were obtained from not treated or serum-treated cells as indicated, in 
presence (Tet +) or absence (Tet -). 
(b) PIM1 knockdown alters H3S10 phosphorylation at the FOSL1 enhancer. Probes A, 
B, C and D are schematized as in Figure 4. Time course analysis by ChIP assay was 
performed by using antibodies as specified from 293 cells expressing either a control 
scrambled shRNA or PIM1 shRNA. A representative experiment is shown. The data 
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represent triplicate real-time quantitative PCR measurements of the 
immunoprecipitated DNA and expressed as 1/1000 (‰) of the DNA inputs.  
 
Figure 6. PIM1 phosphorylates histone H3 in a MYC-dependent manner.  
(a) Inducible MYC gene silencing. 293 were transiently transfected with either a 
control scrambled shRNA (shsM#1) or MYC shRNA (shMYC#1) as indicated by 
tetracycline treatment. Western blot analysis on protein extracts was performed by 
immunoblotting, using antibodies recognising MYC, MAX, or SP1 as indicated.  
(b-e) MYC recruits PIM1 on chromatin. Chromatin samples were obtained from 
serum-induced 293 cells expressing the control scrambled shRNA  or MYC shRNA as 
indicated.  ChIP assays were performed using antibodies as indicated. 
Immunoprecipitated DNA was analyzed by quantitative PCR with primers to amplify 
the FOSL1 enhancer and ID2 upstream MYC-bindig sites (-1705/-1460). A 
representative experiment is shown. The data represent triplicate real-time 
quantitative PCR measurements of the immunoprecipitated DNA and expressed as 
1/1000 (‰) of the DNA inputs.  
(f) Western blot analysis of 293 transiently transfected with control scrambled shRNA 
(shsM#1), MYC shRNA (shMYC#1), or the shRNA together with plasmids expressing 
either FLAG-MYC or FLAG-MYCMBII as indicated. shMYC#1 recognizes MYC 3’-
untranslated region which is not present in the FLAG constructs co-transfected. 
Protein expression was performed by immunoblotting, using antibodies as indicated.  
(g-h) MYC but not FLAG-MYCBMII rescues the recruitment of PIM1 to the 
chromatin. Chromatin samples were obtained from 293 cells expressing the control 
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scrambled shRNA, MYC shRNA, or the shRNA together with FLAG-MYC or FLAG-
MYCMBII (F-MYCMBII) as indicated. ChIP assays were performed using 
antibodies as indicated. Immunoprecipitated DNA was analyzed by quantitative PCR 
with primers to amplify the FOSL1 enhancer and ID2 upstream MYC-binding sites (-
1705/-1460). A representative experiment is shown. The data represent triplicate real-
time quantitative PCR measurements of the immunoprecipitated DNA and expressed 
as 1/1000 (‰) of the DNA inputs.  
 
Figure 7. PIM1 is required for the transcriptional activation of FOSL1 and ID2.  
(a) Schematic representation of the FOSL1 gene region including the first two exons 
(not in scale). Exons are represented as black squares within the gene and the E box 
is figured as a black spot. The probes used in ChIP analysis are indicated. PCR 
probes intervals are numbered relatively to the fist nucleotide of exon 1 (+1). 
(b) Time-course analysis by quantitative real time RT-PCR of FOSL1 mRNA and 
unprocessed heterogeneous nuclear FOSL1 RNA (hnRNA) in 293 cells expressing 
either a control scrambled shRNA or PIM1 shRNA as indicated. Gene specific RNA 
levels at each time point were measured and normalized on GAPDH expression and 
represented as fold induction (vertical bars). A representative experiment is shown. 
The data represent triplicate real-time quantitative RT-PCR measurements.  
(c) Time course analysis by ChIP assay was performed by using antibodies 
recognising RNA Polimerase II (Pol II) or RNA Polimerase  II phosphorylated in its C 
terminal domain at Serine 2 (Ser2P) from 293 cells expressing either a control 
scrambled shRNA or PIM1 shRNA at the FOSL1 promoter or coding region as 
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specified in panel A. A representative experiment is shown. The data represent 
triplicate real-time quantitative PCR measurements of the immunoprecipitated DNA 
and expressed as 1/1000 (‰) of the DNA inputs. 
 (d) Schematic representation of the ID2 gene region including the first two exons (not 
in scale). Exons are represented as black rectangles within the gene and the E box is 
figured as a black spot. The probes used in ChIP analysis are indicated. PCR probes 
intervals are numbered relatively to the fist nucleotide of exon 1 (+1). 
(e) Time-course analysis by quantitative real time RT-PCR of ID2 mRNA and ID2  
hnRNA in 293 cells expressing either a control scrambled shRNA (shsP#1) or PIM1 
shRNA (shPIM1 #1). Gene specific RNA levels at each time point were measured and 
normalized on GAPDH expression and represented as fold induction (vertical bars). A 
representative experiment is shown. The data represent triplicate real-time 
quantitative RT-PCR measurements.  
(f) Time course analysis by ChIP assay was performed by using antibodies 
recognising RNA Polimerase II (Pol II) or RNA Polimerase  II phosphorylated in its C 
terminal domain at Serine 2 (Ser2P) from 293 cells expressing either a control 
scrambled shRNA or PIM1 shRNA at the ID2 promoter or coding region as specified 
in panel D.  
A representative experiment is shown. The data indicated represent triplicate real-time 
quantitative PCR measurements of the immunoprecipitated DNA and expressed as 
1/1000 (‰) of the DNA inputs.  
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Figure 8. PIM1 contributes to MYC-dependent transformation. (a b) Soft agar colony 
formation of Rat-1 cell lines. Rat-1 fibroblasts were transfected with the constructs 
indicated. Transforming potential of the transfected constructs was determined by 
examining the soft agar colonies formed within two weeks post-transfection. 
Transforming potential was estimated by the average number of visible soft agar 
colonies observed in three plates. A representative experiment is shown.  
(c-d) Quantitative real time RT-PCR of FOSL1 and ID2 mRNA in Rat-1 cells 
expressing the constructs indicated. Gene specific RNA levels were measured and 
normalized on GAPDH expression and represented as fold induction (vertical bars). A 
representative experiment is shown. The data represent triplicate real-time 
quantitative RT-PCR measurements.   
(e-f) ChIP assay performed in Rat-1 cells by using antibodies as indicated. The 
primers used for the FOSL1 gene correspond to probe B shown in Figure 4 and for 
the ID2 MYC binding sites as in Figure 7. A representative experiment is shown. The 
data represent triplicate real-time quantitative PCR measurements of the 
immunoprecipitated DNA and expressed as 1/1000 (‰) of the DNA inputs. 
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